Trending...
- IN the Spirit" Spoken Word Documentary Set to Captivate Audiences Worldwide in Summer 2025** - 173
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- PBK Miner completes $80 million Series B financing to support AI cloud mining and increase user investment return by 25%
HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023. Since its founding, Avirmax Biopharma Inc (ABI) has been focusing on developing an effective gene therapy product, ABI-902 for glaucoma treatment. Intravitreal administration of ABI-902 has demonstrated retinal ganglion cell (RGC) protection against N-methyl-D-Asparate (NMDA) excitotoxicity in mice and rats of partial optic nerve transection (pONT) measured by Detection of Apoptosing Retinal Cell (DARC) imaging technology. ABI-902 is manufactured by Avirmax CMC Inc.
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
- WillSexyLove to Release HEAVEN (Feels Like) on June 4th
- Thousands of Cal State LA students to graduate during Commencement 2025
- Amidst Surging IRS Crackdown: Latino Business Owners Find New Hope
- Oakland Airport Electrifies Its Fleet with RIDE Battery-Electric Buses
- Boys & Girls Clubs of Silicon Valley expands with Contra Costa merger
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Filed Under: Business
0 Comments
Latest on The Californer
- Perpetua Resources Corp. (PPTA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Heritage at South Brunswick Grand Opening Success!
- ICYMI: Governor Newsom reassures international partners that Trump's tariffs don't represent California
- Office of Youth Development Announces Youth Power PB (Participatory Budgeting) Long Beach 2025 Awardees
- City of Camarillo Partners With Agromin To Launch Free Compost and Mulch Program
- Michael Baker International Names Fareeha Kibriya Office Executive - Los Angeles and Long Beach
- $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
- LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
- Marc Soucy's Newest Music Series Approaches Its One Year Mark
- Brainomix Presents Robust Validation of Its FDA-Cleared e-Lung Technology from its Collaboration with Boehringer Ingelheim
- MGTT Opens New U.S. Sales Office to Strengthen B2B Support for OEM ODM White Noise Sound Machines
- Fairmint Releases Whitepaper for Open Captable Protocol (OCP) to Advance On-Chain Equity Securities
- Countrywide Fence Rental Expands its Temporary Fence Rental Business in Iowa Area
- Agustina Palma Turns Heads and Defies Protocol at 78th Cannes Film Festival Red Carpet
- Bay Area Riders Break Records on May 15 Bike to Wherever Day
- Spiritual Intelligence Explores a New Vision for Humanity's Evolution
- California: Governor Newsom proclaims Small Business Month 2025
- California: Governor Newsom slams RFK Jr.'s plan to target abortion access with bogus "review" of safe, legal abortion medication
- Justin Sielbach Joins 1200 Lakeshore Apartments
- Relief Alliance Featured on Hollywood Red Carpet in Interview with Johnny Venokur